{"id":"W2164256326","doi":"10.1186/s40064-015-1392-x","title":"A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22","year":2015,"lang":"en","type":"article","venue":"SpringerPlus","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Ottawa; Ottawa Hospital; Queen's University; Sunnybrook Health Science Centre; University of Toronto","funders":"Canadian Cancer Society Research Institute; Ontario Institute for Cancer Research","keywords":"Docetaxel; Medicine; Epirubicin; Oncology; Internal medicine; Breast cancer; Clinical trial; Paclitaxel; Phases of clinical research; Taxane; Chemotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001065972,0.001067159,0.001409252,0.0006290082,0.000351693,0.0008163533,0.0007091174,0.001156442,0.006825462],"category_scores_gemma":[0.0007438886,0.0003779462,0.000574064,0.0005568484,0.0006305081,0.0006053128,0.0003621349,0.002718231,0.001209359],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009018797,"about_ca_system_score_gemma":0.001621182,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001153685,"about_ca_topic_score_gemma":0.005755074,"domain_scores_codex":[0.9996554,0.0001879964,0.00001456946,0.00006325216,0.00002631841,0.00005247956],"domain_scores_gemma":[0.9996238,0.00004366432,0.00006741458,0.00003233116,0.0000220431,0.0002106699],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5976979,0.06348692,0.005067097,0.00138419,0.001026442,0.0002589253,0.0002118356,0.002690516,0.06480611,0.001391524,0.02550537,0.2364732],"study_design_scores_gemma":[0.6833419,0.2830803,0.008010288,0.0001038963,0.0003895661,0.0003809408,0.00004852764,0.00204054,0.004637424,0.0004822543,0.01744224,0.00004218655],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9510189,0.0119692,0.001605155,0.002470233,0.0005226629,0.01376363,0.004402603,0.0005263524,0.01372132],"genre_scores_gemma":[0.9387318,0.005559855,0.006488525,0.00409331,0.0003587636,0.01883617,0.007553567,0.00009050711,0.01828751],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006825462,"threshold_uncertainty_score":0.02283341,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02285095882007512,"score_gpt":0.3156169537537927,"score_spread":0.2927659949337176,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}